Pharmacokinetics and Pharmacodynamics of Lansoprazole in Children with Gastroesophageal Reflux Disease

Pharmacokinetics and Safety of Dexlansoprazole MR in Adolescents With Symptomatic GERD

“…Since approved in 2002 for treating pediatric patients with GERD in the United States, lansoprazole has established its effectiveness and tolerability in patients ages 1 to 17 years for the shortterm treatment of symptomatic GERD and erosive esophagitis (EE) (5). The pediatric use of lansoprazole is supported by evidence from placebo-controlled clinical studies (6)(7)(8)(9) in the adult population with supplemental clinical, pharmacokinetic (PK), and pharmacodynamic studies performed in pediatric patients (10,11). The PK profile of lansoprazole 15 and 30 mg administered for 5 days in adolescents 12 to 17 years of age with GERD was similar to that observed in studies of healthy adults (10).…”

Step-up and step-down approaches to treatment of gastroesophageal reflux disease in children

“…Tolerance or tachyphylaxis does not occur with PPIs. Several studies have shown the effi cacy and tolerability of PPIs in children [33][34][35][36][37][38][39][40]. At present, the only PPIs approved for use in children in the United States are omeprazole, lansoprazole, and (most recently) esomeprazole.…”

Asthma and gastroesophageal reflux disease in children: Exploring the relationship

“…She wondered if there were any alternatives to the use of daily medications.Children such as in this case, particularly those with supraesophageal GERD, often require prolonged gastric acid antisecretory therapy to control their symptoms. As reviewed by Hassall 18 and supported by data from numerous clinical studies 14,18,49,[51][52][53][54][55][56][57][58] daily treatment with a PPI is safe and well-tolerated in the treatment of children with acidrelated disorders (Table). The dosage range of PPI in children is wider than that observed in adults, ranging in pediatric studies from 0.3 to 4.5 mg/kg per day.…”